Vancouver, British Columbia (Newsfile Corp. - November 30, 2016) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical') announces partnership with Dr. David J. Whellan and Thomas Jefferson University in Philadelphia for the design and conduction of clinical trials for its 'Carotid Stenotic Scan (CSS)' device.
Dr. Whellan is the Principal Investigator of Jefferson Regional Clinical Center for the NIH HF Network, one of nine centers across the United States selected to participate in a series of novel heart failure clinical trials. Recognized as preeminent in the cardiovascular healthcare field, his extensive clinical research has produced over 175 peer-reviewed publications on cardiovascular disease, including cardiomyopathy, aspirin use and coronary bypass surgery. His partnership with CVR Global signals a much-anticipated step toward providing evidence regarding the CSS for diagnostic accuracy. With the unique capabilities present at Thomas Jefferson University, the study will compare CSS with existing arterial diagnostic tools across a wide range of potential subjects. CVR executive management looks forward to working with Dr. Whellan and the institution, and expresses great confidence that the upcoming trials will be a thorough and successful vetting that will position the CSS strongly ahead of its market launch.
Commenting on this partnership, Dr. Whellan states, 'We have built a model here at Thomas Jefferson University to engage with companies like CVR Global in the evaluation of novel diagnostics and treatments for a wide variety of patients. What drew us to this project is that it's a technology that fits within our emphasis on innovation. We want to be a leading organization for the evaluation of novel therapies and diagnostic technologies.'
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD: (signed) 'Peter Bakema' CEO, President & Director
For further information contact:
Brisco Capital Partners Corp. Scott Koyich, President Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Click on, or paste the following link into your web browser, to view the associated documents
News Source: Newsfile
30.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Company: CVR Medical Corp.
End of News DGAP News Service
Nachricht von reuters.com: * Helix Biopharma Corp accelerates escalation of L-DOS47
dosing in the U S . BRIEF-Helix Biopharma accelerates escalation of L-DOS47 dosing in the U.S. Phase I study. Phase I study weiterlesen ...
Artikel von washingtonpost.com:
Updated at 6:28 a m Normal service is back on Metro’s Red Line after a morning that involved several problems, including a deer that was hit by a train outside the Fort Totten stop, a smoking insulator near the Medical Center stop and a broken-down train at the Tenleytown stop . Earlier delays on Metro’s Red Line after multiple problems, including a deer and a smoking insulator. Red Line: Normal service has resumed outside Tenleytown. … weiterlesen ...
Dazu berichtet reuters.com weiter: * Delivra reports record Q3 revenues and licensing agreement
for the transdermal delivery of medical cannabis during the
quarter . BRIEF-Delivra reports Q3 loss per share of c$0.06. weiterlesen ...
reuters.com berichtet dazu: * Helix Biopharma Corp accelerates escalation of l-dos47
dosing in the U S . BRIEF-Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study. Phase I study weiterlesen ...
Dazu rss.dw.de weiter: North Dakota governor orders oil pipeline protesters expelled weiterlesen ...
Dazu schreibt rss.dw.de: Deadly car bomb hits Somalia marketplace weiterlesen ...
rss.dw.de schreibt: Suicide truck bomb in Iraqi kills scores of Shiite pilgrims weiterlesen ...
Dazu schreibt rss.dw.de: How expensive would US-made iPhones be? weiterlesen ...
Dazu berichtet rss.dw.de: Kanye West hospitalized after erratic behavior weiterlesen ...
Weitere Nachricht von rss.dw.de: Aleppo hospitals out of service as Syrian regime intensifies assault weiterlesen ...